Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim in Pediatric Crohn's Disease
NCT00206661Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Dec 2004
- Primary completion
- Dec 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sargramostim in Crohn's disease (2 arms), sponsored by Sanofi. Primary endpoint: Characterize the safety profile of sargramostim treatment at 12 weeks. Started Dec 2004; status: terminated.
02
Drugs
sargramostim
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00206661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206661.